Treatment with HTR1B antagonists reduced chronic myeloid clonal neoplasms cell viability and showed a synergistic cytotoxic effect with currently approved hypomethylating agents in AML cells [40]. This evidence concerns the gene HTR1B and acute myeloid leukemia.